Stevens Johnson Syndrome/Toxic Epidermal Necrolysis – Diagnostic Testing and Treatment for Ophthalmologists

Abstract

Epidermal necrolysis (EN) is a very rare, but life-threatening dermatological disease where the skin and various mucous membranes react to drugs (75%) or systemic infections (25%). If up to 10% of the body surface is affected, the disease is called Stevens Johnson syndrome (SJS); if more than 30% of the body surface is affected, it is called toxic epidermal necrolysis (TEN); if 10 – 30% of the body surface is affected, it is called SJS/TEN overlap. In the acute phase of the disease, 80% of cases show ophthalmic involvement (from mild conjunctivitis to total de-epithelialisation of the ocular surface). Therefore, patients should be seen by an ophthalmologist within 24 h after symptoms have started. Treatment of the acute ophthalmic problems has a very important impact on long-term eye complications. However, in the long run up to 50% of patients develop chronic sight threatening ocular surface disease which needs further intensive topical and surgical treatment (e.g. lubrification, topical anti-inflammatory agents, lid surgery, scleral lenses, corneal surgery). The indication for corneal transplantation (allogenic penetrating limbo-keratoplasty and keratoprostheses) should be given with due caution, as the prognosis is very poor.

Keywords

conjunctiva - cornea - lids

Publikationsverlauf

Eingereicht: 20. Januar 2025

Angenommen: 13. Februar 2025

Artikel online veröffentlicht:
16. Juni 2025

• References/Literatur

• 1 Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102: 28S-30S
• 2 Stevens AM, Johnson FC. A New Eruptive Fever Associated with Stomatitis and Ophthalmia: Report of two Cases in Children. JAMA Pediatr 1922; 24: 526-533
• 3 Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361
• 4 Frantz R, Huang S, Are A. et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas) 2021; 57: 895
• 5 Bastuji-Garin S, Fouchard N, Bertocchi M. et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153
• 6 Haber J, Hopman W, Gomez M. et al. Late outcomes in adult survivors of toxic epidermal necrolysis after treatment in a burn center. J Burn Care Rehabil 2005; 26: 33-41
• 7 Chang YS, Huang FC, Tseng SH. et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007; 26: 123-129
• 8 Hsu DY, Brieva J, Silverberg NB. et al. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J Invest Dermatol 2016; 136: 1387-1397
• 9 Frey N, Jossi J, Bodmer M. et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol 2017; 137: 1240-1247
• 10 Chaby G, Maldini C, Haddad C. et al. Incidence of and mortality from epidermal necrolysis (Stevens‐Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four‐source capture-recapture estimate. Br J Dermatol 2020; 182: 618-624
• 11 Yang SC, Hu S, Zhang SZ. et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. J Immunol Res 2018; 2018: 1-10
• 12 Sassolas B, Haddad C, Mockenhaupt M. et al. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis. Clin Pharmacol Ther 2010; 88: 60-68
• 13 Mockenhaupt M, Viboud C, Dunant A. et al. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study. J Invest Dermatol 2008; 128: 35-44
• 14 Mockenhaupt M. Bullous Drug Reactions. Acta Derm Venereol 2020; 100: adv00057
• 15 Stanley E, Zhang L, OʼHara J. et al. The Seven-Fold Rise in Incidence of Stevens-Johnson Syndrome & Toxic Epidermal Necrolysis: Associations with COVID-19 and the Vaccine. Burns 2024; 50: 87-92
• 16 Zou H, Daveluy S. Toxic epidermal necrolysis and Stevens-Johnson syndrome after COVID-19 infection and vaccination. Australas J Dermatol 2023; 64: e1-e10
• 17 Mockenhaupt M. [Severe cutaneous drug reactions in children]. Hautarzt 2017; 68: 803-814
• 18 Lin M, Gong T, Ruan S. et al. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy. J Inflamm Res 2024; 17: 2337-2351
• 19 Ardern-Jones M, Mockenhaupt M. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol 2019; 19: 283-293
• 20 Lonjou C, Thomas L, Borot N. et al. A marker for Stevens-Johnson syndrome …: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268
• 21 U.S. Food and Drug Administration (FDA). Table of Pharmacogenetic Associations. https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations Stand: 13.03.2025
• 22 Ueta M. Findings by an International Collaboration on SJS/TEN With Severe Ocular Complications. Front Med 2021; 8: 649661
• 23 Hung SI, Mockenhaupt M, Blumenthal KG. et al. Severe cutaneous adverse reactions. Nat Rev Dis Primers 2024; 10: 30
• 24 Klimas N, Quintanilla-Dieck J, Vandergriff T. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Hall JC, Hall BJ. eds. Cutaneous Drug Eruptions. London: Springer Nature; 2015: 259-269
• 25 Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009; 7: 142-160
• 26 Tóth G, Lukács A, Schirra F. et al. Ophthalmic Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review. Ophthalmol Ther 2023; 12: 1795-1811
• 27 Sotozono C, Ueta M, Yokoi N. Severe Dry Eye With Combined Mechanisms is Involved in the Ocular Sequelae of SJS/TEN at the Chronic Stage. Invest Ophthalmol Vis Sci 2018; 59: DES80-DES86
• 28 Kim MK, Yoon KC, Yoon S. et al. Clinical Aspects of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Severe Ocular Complications in South Korea. Front Med 2021; 8: 640360
• 29 Abrol A, Gulanikar A, Thakre S. et al. Study of Ocular Manifestations of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Indian Dermatol Online J 2020; 11: 570-574
• 30 Catt C, Hamilton G, Fish J. et al. Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. Am J Ophthalmol 2016; 166: 68-75
• 31 Kang M. Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Hanyang Med Rev 2016; 36: 174
• 32 Gregory D. New Grading System and Treatment Guidelines for the Acute Ocular Manifestations of Stevens-Johnson Syndrome. Ophthalmology 2016; 123: 1653-1658
• 33 Gueudry J, Roujeau JC, Binaghi M. et al. Risk Factors for the Development of Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Arch Dermatol 2009; 145: 157-162
• 34 Jongkhajornpong P, Lekhanont K, Siriyotha S. et al. Factors Contributing to Long-Term Severe Visual Impairment in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Ophthalmol 2017; 2017: 2087578
• 35 Lee HY, Walsh SA, Creamer D. Long term complications of Stevens-Johnson syndrome/Toxic epidermal necrolysis: The spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multi-disciplinary follow up. Br J Dermatol 2017; 177: 924-935
• 36 Yang CW, Cho YT, Chen KL. et al. Long-term Sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Acta Derm Venereol 2016; 96: 525-529
• 37 Sotozono C, Ueta M, Nakatani E. et al. Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Am J Ophthalmol 2015; 160: 228-237.e2
• 38 Chronopoulos A, Mockenhaupt M, Pleyer U. Okuläre Beteiligung bei Stevens-Johnson-Syndrom und bei Toxisch epidermaler Nekrolyse. Klin Monbl Augenheilkd 2012; 229: 534-539
• 39 Rojas M, Dart J, Saw V. The natural history of Stevens-Johnson syndrome: Patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007; 91: 1048-1053
• 40 Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012; 167: 424-432
• 41 Zimmermann S, Sekula P, Venhoff M. et al. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis. JAMA Dermatol 2017; 153: 514-522
• 42 Arévalo J, Lorente J, González-Herrada C. et al. Treatment of Toxic Epidermal Necrolysis with Cyclosporin A. J Trauma 2000; 48: 473-478
• 43 Valeyrie-Allanore L, Wolkenstein P, Brochard L. et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010; 163: 847-853
• 44 González-Herrada C, Rodríguez-Martín S, Cachafeiro L. et al. Ciclosporin Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J Invest Dermatol 2017; 137: 2092-2100
• 45 Cao J, Zhang X, Xing X. et al. Biologic TNF-α Inhibitors for Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis. Dermatol Ther (Heidelb) 2023; 13: 1305-1327
• 46 Metcalfe D, Iqbal O, Chodosh J. et al. Acute and Chronic Management of Ocular Disease in Stevens Johnson Syndrome/Toxic Epidermal Necrolysis in the USA. Front Med 2021; 8: 662897
• 47 Jain R, Sharma N, Basu S. et al. Stevens Johnsons Syndrome: The Role of an Ophthalmologist. Surv Ophthalmol 2016; 61: 369-399
• 48 Matsumoto K, Ueta M, Inatomi T. et al. Topical Betamethasone Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Involvement in the Acute Phase. Am J Ophthalmol 2023; 253: 142-151
• 49 Sharma N, Venugopal R, Singhal D. et al. Microbial Keratitis in Stevens-Johnson Syndrome: A Prospective Study. Cornea 2019; 38: 938-942
• 50 Shanbhag SS, Hall L, Chodosh J. et al. Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. Ocul Surf 2020; 18: 517-522
• 51 Sharma N, Thenarasun SA, Kaur M. et al. Adjuvant Role of Amniotic Membrane Transplantation in Acute Ocular Stevens-Johnson Syndrome. Ophthalmology 2015; 123: 484-491
• 52 Pinna A, Nuvoli E, Blasetti F. et al. Plasmapheresis, Intravenous Immunoglobulins, and Autologous Serum Eyedrops in the Acute Eye Complications of Toxic Epidermal Necrolysis. Eur J Ophthalmol 2017; 27: 658-663
• 53 Prabhasawat P, Tesavibul N, Karnchanachetanee C. et al. Efficacy of Cyclosporine 0.05 % Eye Drops in Stevens Johnson Syndrome with Chronic Dry Eye. J Ocul Pharmacol Ther 2013; 29: 372-377
• 54 Fogagnolo P, Cilla S, Alkabes M. et al. A Review of Topical and Systemic Vitamin Supplementation in Ocular Surface Diseases. Nutrients 2021; 13: 1998
• 55 Ravindra A, Sinha R, Bari A. et al. Retinol palmitate in management of chronic Steven-Johnson Syndrome with ocular surface keratinization. Ocul Surf 2023; 30: 160-167
• 56 Singh S, Basu S, Jakati S. Cicatricial Entropion in Chronic Cicatrizing Conjunctivitis: Potential Pathophysiologic Mechanisms and Long-Term Outcomes of a Modified Technique. Ophthal Plast Reconstr Surg 2023; 39: 563-569
• 57 Tougeron-Brousseau B, Delcampe A, Gueudry J. et al. Vision-Related Function After Scleral Lens Fitting in Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Am J Ophthalmol 2009; 148: 852-859.e2
• 58 Papakostas TD, Le HG, Chodosh J. et al. Prosthetic replacement of the ocular surface ecosystem as treatment for ocular surface disease in patients with a history of Stevens-Johnson syndrome/toxic epidermal necrolysis. Ophthalmology 2015; 122: 248-253
• 59 Akyol-Salman I, Azizi S, Mumcu U. et al. Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. J Ocul Pharmacol Ther 2010; 26: 329-333
• 60 Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin 2000; 40: 113-122
• 61 Reinhard T, Spelsberg H, Henke L. et al. Long-term results of allogeneic penetrating limbo-keratoplasty in total limbal stem cell deficiency. Ophthalmology 2004; 111: 775-782
• 62 Reinhard T, Sundmacher R, Spelsberg H. et al. Homologous penetrating central limbo-keratoplasty (HPCLK) in bilateral limbal stem cell insufficiency. Acta Ophthalmol Scand 1999; 77: 663-667
• 63 Lang SJ, Böhringer D, Geerling G. et al. Long-term results of allogenic penetrating limbo-keratoplasty: 20 years of experience. Eye (Lond) 2016; 31: 372-378
• 64 Angerer MPM, Weller JM, Kruse FE. et al. Long-Term Outcomes of Keratoprosthesis With Biological Haptic: A Review of 25 Years of Single-Center Surgeries. Cornea 2024; 43: 1137-1143
• 65 Saini C, Chen TC, Young LH. et al. Restoration of Vision in Severe, Cicatricial, Ocular Surface Disease With the Boston Keratoprosthesis Type II. Am J Ophthalmol 2022; 243: 42-54
• 66 AWMF online. S3-Leitlinie Diagnostik und Therapie der epidermalen Nekrolyse (Stevens-Johnson-Syndrom und toxisch epidermale Nekrolyse) SJS-TEN. 2024. https://register.awmf.org/assets/guidelines/013-103l_S3_Diagnostik-Therapie-epidermale-Nekrolyse-Stevens-Johnson-Syndrom-toxisch-epidermale-Nekrolyse-SJS-TEN_2024-11.pdf Stand: 13.03.2025
• 67 Heuer R, Paulmann M, Annecke T. et al. S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy. J Dtsch Dermatol Ges 2024; 22: 1448-1466
• 68 Paulmann M, Heuer R, Annecke T. et al. S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) – Part 2: Supportive therapy of EN in the acute and post-acute stages. J Dtsch Dermatol Ges 2024; 22: 1576-1593